MEI Pharma, Inc. (MEIP)
$3.07+10.43%Close
SELLCRISIS · day 6
Key stats
- Market cap
- $20M
- Beta
- 0.22
- P/E (TTM)
- -1.53
- 1W
- -32.23%
- 1M
- -36.44%
- vs SPY 1W
- -32.65%
- vs SPY 1M
- -38.50%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 3
- GROWTH
- 4
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-54.5%
REV YoY-
ROE-90.8%
EPS YoY-
ROA-105.2%
GROSS50
OP-4857
NET-5085
[VALUATION]
P/E TTM-1.53
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B1.93
P/FCF-
EV/EBITDA-0.22
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO11.53
ND/EBITDA-
BETA0.22
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on MEIP?
- LOPJLB’s latest quantitative signal on MEI Pharma, Inc. (MEIP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MEIP in?
- MEI Pharma, Inc. (MEIP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MEI Pharma, Inc. (MEIP) do?
- MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm st…